Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 14,069 Cr.
- Current Price ₹ 588
- High / Low ₹ 737 / 469
- Stock P/E 37.9
- Book Value ₹ 98.6
- Dividend Yield 0.00 %
- ROCE 29.0 %
- ROE 26.9 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 88.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE IPO Nifty MidSmallcap 400 Nifty 500 Multicap 50:25:25 Nifty Total Market BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,710 | |
511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,167 | |
Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 543 |
OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 20% |
7 | -102 | -3 | -21 | 58 | 79 | 83 | |
Interest | 6 | 9 | 7 | 6 | 31 | 49 | 40 |
Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 76 |
Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 510 |
Tax % | 45% | 191% | 23% | 28% | 27% | 27% | |
14 | -12 | 149 | 163 | 266 | 337 | 373 | |
EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.21 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | 39% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 88% |
3 Years: | 32% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 29% |
Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 |
Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,312 |
147 | 483 | 51 | 66 | 502 | 490 | 88 | |
108 | 222 | 220 | 524 | 638 | 627 | 576 | |
Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,024 |
104 | 119 | 86 | 138 | 664 | 646 | 632 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 13 | 0 | 120 | 614 | 796 | 917 |
225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,475 | |
Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,024 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
65 | 22 | 172 | 297 | 130 | 508 | |
-18 | -16 | -81 | -158 | -896 | -326 | |
-21 | 136 | -132 | 233 | 333 | -66 | |
Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 60 | 127 | 108 | 97 | 102 | 91 |
Inventory Days | ||||||
Days Payable | ||||||
Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 91 |
Working Capital Days | 23 | 64 | 53 | 16 | 45 | 40 |
ROCE % | 37% | 55% | 46% | 33% | 29% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Of Schedule of Investor / Analyst meeting under the SEBI (LODR), Regulations, 2015
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 2d
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Indegene wins Deloitte Technology Fast 50 India 2024 Award.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
6 Dec - Disclosure of release of indirect encumbrance over shares.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
6 Dec - Disclosure of share acquisition by CA Dawn Investments.
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.